Investor Alert: Rosen Law Firm Targets Atara Biotherapeutics and Hitek Global in New Lawsuits

2026-03-25 companies

New York, Thursday, 26 March 2026.
On March 25, 2026, Rosen Law Firm alerted shareholders of Atara Biotherapeutics and Hitek Global to pending legal actions involving allegedly misleading corporate disclosures that severely impacted investor value.

Regulatory Hurdles and Clinical Setbacks for Atara Biotherapeutics

The core of the litigation against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on the company’s Biologics License Application for its treatment candidate, tabelecleucel [1]. The lawsuit alleges that between May 20, 2024, and January 9, 2026, the company issued false or misleading statements regarding its prospects for approval from the Food and Drug Administration [1]. Central to these claims are purported manufacturing deficiencies and structural shortcomings within the ALLELE clinical study, which ultimately made regulatory clearance highly improbable [1].

Expanding Scrutiny: Hitek Global and Broader Investigations

Parallel to the Atara lawsuit, Rosen Law Firm announced on March 25, 2026, an active investigation into Hitek Global Inc. (NASDAQ: HKIT) [2]. This inquiry is scrutinizing allegations that the company may have disseminated materially misleading business information to the public [2]. While a formal class action has not yet been certified, the firm is currently preparing litigation aimed at recovering losses for Hitek shareholders through a contingency fee arrangement, which requires no upfront costs from investors [2].

A Wave of Financial Disclosures and Market Reactions

The legal actions against Atara and Hitek are part of a broader surge in shareholder litigation led by Rosen Law Firm in late March 2026 [2][5][6][7][8]. On March 24, the firm opened an investigation into PennyMac Financial Services, Inc. (NYSE: PFSI) following a dramatic earnings miss [5]. On January 29, 2026, PennyMac disclosed a servicing segment pretax income of $37.3 million, representing a steep decline of -76.302 percent from the $157.4 million reported in the prior quarter [5]. The following day, the market reacted severely, with PennyMac’s stock plummeting $49.78 per share to close at $99.92 [5].

Accountability in Corporate Governance

Adding to this wave of litigation, Lakeland Industries, Inc. (NASDAQ: LAKE) is facing scrutiny over its financial guidance and operational disclosures [8]. A class action lawsuit alleges that between December 1, 2023, and December 9, 2025, Lakeland provided unreliable financial guidance and overstated the strength of its tariff mitigation measures [8]. The suit also claims the company failed to disclose underlying issues with its Pacific Helmets and Jolly business segments, ultimately resulting in investor damages [8]. Shareholders have until April 24, 2026, to file motions to serve as lead plaintiff in the Lakeland case [8].

Sources

Securities litigation Shareholder rights